Effect of vasoactive intestinal peptide on serotonin release in the suprachiasmatic area of the rat. Modulation by oestradiol.
The effect of vasoactive intestinal peptide (VIP) on spontaneous and induced release of newly synthesized 5-hydroxytryptamine (5-HT) was studied in the suprachiasmatic area (SCA) using a superfusion system. To test the possible modulation by E2 on the interaction VIP-5-HT, the experiments were conducted on male, ovariectomized (OVX) and ovariectomized oestradiol implanted rats (OVX-E2). VIP (10(-7)M) infused for 15 min caused an increase of 5-HT release from SCA of male and OVX. The positive effect of VIP on 5-HT release results partially from an inhibition of the reuptake of 5-HT: in male and OVX SCA, VIP inhibited the 3H-5-HT uptake by 40 to 50%. The infusion of VIP before a pulse of K+ (10-20-30-56 mM) leads to a potentialisation of the evoked release suggesting that VIP sensitized the presynaptic membrane to the process linking depolarization and release. When SCA taken from OVX-E2 were exposed to VIP, 5-HT uptake and consequently 5-HT release were unchanged. The present results suggest that the metabolism of 5-HT in the SCA is influenced by VIP and that this regulation may be modulated by E2. This interaction between E2, VIP and 5-HT at the SCA level may be involved in the regulation of phasic LH and prolactin surge.
D000818:Animals; D002369:Castration; D004958:Estradiol / Q000494:pharmacology*; D005260:Female; D066298:In Vitro Techniques; D008297:Male; D010053:Ovary / Q000502:physiology; D010477:Perfusion; D051381:Rats; D011919:Rats, Inbred Strains; D012701:Serotonin / Q000096:biosynthesis / Q000378:metabolism; D013493:Suprachiasmatic Nucleus / Q000187:drug effects / Q000378:metabolism*; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*
D012701:Serotonin; D014660:Vasoactive Intestinal Peptide; D004958:Estradiol